AstraZeneca signs a deal worth up to $247M with US-based Absci Corp. to harness Absci's AI tech for large-scale protein analysis to find a viable cancer therapy — Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Posted from: this blog via Microsoft Power Automate.